Drug intelligence / Profile preview

KNA-129

Development stage: Unknown
Lead developer: Kinea Bio
Modality: Gene Therapies

Overview

KNA-129 is an investigational gene therapy developed by Kinea Bio for the treatment of myotonic dystrophy, a neuromuscular disorder characterized by progressive muscle wasting and weakness. The drug is currently in the discovery phase of development, with its primary therapeutic area being nervous system diseases, specifically targeting congenital disorders such as myotonic dystrophy. Detailed information about its mechanism of action or specific genetic targets has not been disclosed publicly[1][3].

Beyond the preview

Go deeper on KNA-129.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KNA-129.

Explore the full profile